Similar Papers

Paper Title
Journal
Date
Author
Predictive value of faecal calprotectin in ulcerative colitis – single centre experience
Dora Grgić ... Željko Krznarić
Annals of Medicine | VOL. 54
Dora Grgić, et. al.Dora Grgić ... Željko Krznarić
30 May 2022
P-099: Single center experience with infliximab in Japanese children with ulcerative colitis
H Shimizu ... K Arai
Journal of Crohn's and Colitis | VOL. 8
H Shimizu, et. al.H Shimizu ... K Arai
01 Sep 2014
Characteristics of Patients Treated With Vedolizumab for Inflammatory Bowel Disease in the United States
Reema Mody ... Haridarshan Patel
American Journal of Gastroenterology | VOL. 110
Reema Mody, et. al.Reema Mody ... Haridarshan Patel
01 Oct 2015
Efficacy of biological treatment in inflammatory bowel disease – a single-center experience
Agata Michalak ... Marek Cybulski
Polish Journal of Public Health | VOL. 129
Agata Michalak, et. al.Agata Michalak ... Marek Cybulski
01 Sep 2019
View more papers

More From: American Journal of Gastroenterology

Paper Title
Journal
Date
Author
Quality Indicators for EUS
Girish Mishra ... B Joseph Elmunzer
American Journal of Gastroenterology | VOL. -
Girish Mishra, et. al.Girish Mishra ... B Joseph Elmunzer
23 Apr 2025
Accurately Predicting Recurrent Primary Sclerosing Cholangitis After Liver Transplantation
Ming Gao ... Xuefeng Ma
American Journal of Gastroenterology | VOL. -
Ming Gao, et. al.Ming Gao ... Xuefeng Ma
07 Apr 2025
A Risk Stratification Tool for Relapse After Intravenous-to-Subcutaneous Switching of Infliximab in Patients with Inflammatory Bowel Diseases
Yannick Hoffert ... Erwin Dreesen
American Journal of Gastroenterology | VOL. -
Yannick Hoffert, et. al.Yannick Hoffert ... Erwin Dreesen
07 Apr 2025
LONG-TERM SUSTAINED IMPROVEMENT IN UNPLANNED HEALTHCARE UTILIZATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
Gil Y Melmed ... Corey A Siegel
American Journal of Gastroenterology | VOL. -
Gil Y Melmed, et. al.Gil Y Melmed ... Corey A Siegel
07 Apr 2025
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.